Ann Clin Microbiol.  2021 Jun;24(2):55-60. 10.5145/ACM.2021.24.2.1.

Evaluation of Seroprevalence of SARS-CoV-2 IgG in Healthcare Workers in a Tertiary Hospital in Seoul

• Nam M
• Moon HW
• Kim H
• Hur M
• Yun YM

• KMID: 2516727
• DOI: http://doi.org/10.5145/ACM.2021.24.2.1

Abstract

Healthcare workers (HCWs) may be at high risk for exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of their frequent contact with patients or the direct handling of respiratory samples. We investigated the seroprevalence of SARS-CoV-2 IgG in HCWs in Seoul compared to those in coronavirus disease (COVID-19) patients and community-based individuals to evaluate the antibody response. A total of 358 samples from 348 individuals (155 HCWs, 7 COVID-19 patients, and 186 community-based individuals) were collected from April to November 2020. SARS-CoV-2 IgG was detected in 1 of 155 HCWs (1 of 46 HCWs with direct contact), 7 of 7 COVID-19 patients, and none of the 186 communitybased individuals (95% CI: 0.6%, 0.1 - 3.6%; 100%, 64.5 - 100%; 0.0%, 0.0 - 2.0%, respectively). The single HCW with a positive result showed 2.32 signal-to-cutoff (S/C) and 2.31 S/C at a 3-week interval. Therefore, it was assumed to be a false positive due to autoantibody or medication. The positive samples from 7 patients had a median of 3.79 S/C (range 1.72 - 6.54). The seroprevalence of SARS-CoV-2 IgG in HCWs was very low. The current infection control standard seems to be effective in protecting HCWs from COVID-19.

Keyword

Healthcare workers; SARS-CoV-2 IgG; Seroprevalence

Reference

1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2020;6:1-14.

2. WHO. Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/ diseases/novel-coronavirus-2019. [Online] (last visited on 1 October 2020).

3. Korea Disease Control and Prevention Agency (KDCA). Coronavirus disease (COVID-19). http://ncov.mohw.go.kr/en/bdBoardList.do?brdId=16&brdGubun=162&dataGubun=&ncvContSeq=&contSeq=&board_id=. [Online] (last visited on 1 October 2020).

4. Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The role of antibody testing for SARS-CoV-2: is there one? J Clin Microbiol 2020;58:e00797-20.

5. Korea Disease Control and Prevention Agency (KDCA). Management guidelines for coronavirus disease-19. Version 9. http://ncov.mohw.go.kr/duBoardList.do?brdId=2&brdGubun=24. [Online] (last visited on 4 December 2020).

6. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in health care workers: a systematic review and metaanalysis. J Hosp Infect 2020;S0195-6701:30522.

7. Jääskeläinen AJ, Kuivanen S, Kekäläinen E, Ahava MJ, Loginov R, Kallio-Kokko H, et al. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Viol 2020;129:104512.

8. Manalac J, Yee J, Calayag K, Nguyen L, Patel PM, Zhou D, et al. Evaluation of Abbott antiSARS-CoV-2 CMIA IgG and Euroimmune ELISA IgG/IgA assays in a clinical lab. Clin Chim Acta 2020;510:687–90.

9. Chen SY, Lee YL, Lin YC, Lee NY, Liao CH, Hung YP, et al. Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerg Microbes Infect 2020;9:2157-68.

10. Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Ghogomu ET, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015;18:CD005468.

11. Noh JY, Seo YB, Yoon JG, Seong H, Hyun H, Lee J, et al. Seroprevalence of anti-SARSCoV-2 antibodies among outpatients in southwestern Seoul, Korea. J Korean Med Sci 2020;35:e311.

12. Pearce N, Lawlor DA, Brickley EB. Comparisons between countries are essential for the control of COVID-19. Int J Epidemiol 2020;47:1059-62.

13. Yoo JY, Dutra SVO, Fanfan D, Sniffen S, Wang H, Siddiqui J, et al. Comparative analysis of COVID-19 guidelines from six countries: a qualitative study on the US, China, South Korea, the UK, Brazil, and Haiti. BMC Public Health 2020;20:1853.

14. Naaber P, Hunt K, Pesukova J, Haljasmagi L, Rumm P, Peterson P, et al. Evaluation of SARSCoV-2 IgG antibody response in PCR positive patients: comparison of nine tests in relation to clinical data. PLoS One 2020;15:e0237548.

15. Elslande JV, Decru B, Jonckheere S, Wijngaerden EV, Houben E, Vandecandelaere P, et al. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect 2020;26:1557.e1-7.